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An open label randomized controlled trial on the efficacy of adding intranasal fentanyl 
to intravenous tramadol in patients with moderate to severe pain following acute 
musculoskeletal injuries 
 
Introduction: Intra-nasal fentanyl, as an alternative route of analgesic administration, has 
been shown to be effective particularly in pediatric population and in prehospital setting.  
Studies on such use among adult patients in emergency department are limited. Methods: An 
open-label study was conducted to evaluate the effectiveness of adding 1.5 mcg/kg intranasal 
fentanyl on top of 2 mg/kg intravenous tramadol (FENTANYL_TRAMADOL, n = 10) as 
compared to 2 mg/kg intravenous tramadol alone (TRAMADOL, n = 10) in adult patients 
with acute musculoskeletal injuries in moderate to severe pain.  Results:  When analyzed 
using independent t-test, the mean visual analog scale (VAS) difference between pre- and 10-
minute post-intervention was found to be 29.8 mm (SD +/- 8.4 mm) in the 
FENTANYL_TRAMADOL arm and 19.6 mm (SD +/- 9.7 mm) in the TRAMADOL arm 
[t(8) = 2.515, p = 0.022, 95% confidence interval (CI) 1.68 to 18.72 mm].  A significantly 
greater albeit transient reduction in mean arterial pressure 10 minutes post-intervention was 
noted in the FENTANYL_TRAMADOL arm as compared to those in the TRAMADOL arm 
(13.35 mmHg vs 7.65 mmHg, using Mann-Whitney U test with U-value = 21.5; p = 0.029; r 
= 0.48). Patients in the FENTANYL_TRAMADOL arm also experienced a higher incidence 
of transient dizziness 10 minutes post-intervention. Conclusion: Although effective, intra-
nasal fentanyl in adult patients may not be ready for primetime as it may result in significant 






Kajian rawak label terbuka efikasi penggunaan intranasal fentanyl bersama intravena 
tramadol pada pesakit tahap kesakitan sedang dan teruk disebabkan kecederaan otot 
dan tulang akut 
 
Pengenalan : Intra-nasal fentanyl sebagai laluan administrasi analgesic alternative telah 
terbukti efektif lebih-lebih lagi pada populasi pediatrik dan untuk kegunaan prehospital. 
Kajian pada populasi dewasa masih terhad. Metodologi : Kajian label terbuka dibuat untuk 
menilai tahap efektif penambahan 1.5 mcg/kg intranasal fentanyl ke atas 2 mg/kg intravena 
tramadol (FENTANYL_TRAMADOL, n = 10) berbanding penggunaan 2 mg/kg intravena 
tramadol secara bersendirina (TRAMADOL, n = 10) pada pesakit dewasa yang mempunyai 
kecederaan tulang dan otot akut dengan tahap kesakitan sedang  sehingga teruk. Keputusan : 
Analisis di buat menggunakan ‘independent t-test ’, perbezaan min ‘visual analogue scale 
(VAS)’ sebelum dan 10 minit selepas intervensi adalah 29.8 mm (SD +/- 8.4 mm) untuk 
kumpulan FENTANYL_TRAMADOL dan 19.6 mm (SD +/- 9.7 mm) untuk kumpulan 
TRAMADOL [t(8) = 2.515, p = 0.022, 95% confidence interval (CI) 1.68 to 18.72 mm]. 
Penurunan signifikan ‘mean arterial pressure (MAP)’ yang berlaku sementara  terjadi pada 
minit ke 10 selepas intervensi dapat dilihat pada kumpulan FENTANYL_TRAMADOL 
berbanding kumpulan TRAMADOL (13.35 mmHg vs 7.65 mmHg, Mann-Whitney U test 
with U-value = 21.5; p = 0.029; r = 0.48). Pesakit kumpulan FENTANYL_TRAMADOL 
juga mengalami simptom pening yang lebih tinggi berbanding kumpulan TRAMADOL tetapi 
ia berlaku hanya untuk waktu sementara 10 minit selepas intervensi. Konklusi : Walaupun 
efektif, fentanyl intranasal untuk pesakit dewasa masih belum bersedia untuk digunakan 
secara meluas disebabkan ia dapat menyebabkan penurunan tekanan darah yang signifikan.  
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Introduction: Intra-nasal fentanyl, as an alternative route of analgesic administration, 
has been shown to be effective particularly in pediatric population and in prehospital setting.  
Studies on such use among adult patients in emergency department are limited.  
 
Objectives: The aim of this study was To compare intranasal fentanyl with 
intravenous tramadol as analgesia with intravenous tramadol 
 
Methods: An open-label study was conducted to evaluate the effectiveness of adding 
1.5 mcg/kg intranasal fentanyl on top of 2 mg/kg intravenous tramadol 
(FENTANYL_TRAMADOL, n = 10) as compared to 2 mg/kg intravenous tramadol alone 
(TRAMADOL, n = 10) in adult patients with acute musculoskeletal injuries in moderate to 
severe pain.  
 Results:  When analyzed using independent t-test, the mean visual analog scale 
(VAS) difference between pre- and 10-minute post-intervention was found to be 29.8 mm 
(SD +/- 8.4 mm) in the FENTANYL_TRAMADOL arm and 19.6 mm (SD +/- 9.7 mm) in the 
TRAMADOL arm [t(8) = 2.515, p = 0.022, 95% confidence interval (CI) 1.68 to 18.72 mm].  
A significantly greater albeit transient reduction in mean arterial pressure 10 minutes post-
intervention was noted in the FENTANYL_TRAMADOL arm as compared to those in the 
TRAMADOL arm (13.35 mmHg vs 7.65 mmHg, using Mann-Whitney U test with U-value = 
21.5; p = 0.029; r = 0.48). Patients in the FENTANYL_TRAMADOL arm also experienced a 
higher incidence of transient dizziness 10 minutes post-intervention.  
 
Conclusion: Although effective, intra-nasal fentanyl in adult patients may not be 
ready for primetime as it may result in significant reduction in blood pressure. 
 







 Pain is the most common reason for patients come attending the emergency 
department (ED) (Tanabe and Buschmann, 1999a). Adequate analgesia in EDs is an 
important goal of treatment. In emergency department pain intensity is high, and most of the 
time analgesics are underutilized at the same time delays to treatment are common. Most 
patients whom presented to ED with complain of pain expected rapid delivery of pain 
medication after arrival in ED (Fosnocht et al., 2001). According to Grant (2006), there was a 
significant delay in patients with acute pain receiving any form of analgesia.  
 
In United States and Canada, the median time interval from triage to analgesic 
administration was 90 minutes and it was stated in a study that only 29% of patients who 
were given analgesics received them within 1 hour of arrival. The most common analgesics 
administered were opiods and morphine being the most commonly used followed by 
ibuprofen (Todd et al., 2007). 
 
In certain cases, physician working in ED need to consider certain pertinent issues 
such as ease of intravenous (IV) access and patient preference for analgesia route of 
administration and most of the time for patient with severe pain, intravenous analgesia is 
usually preferable (Thomas, 2013). However there are few other available routes that promise 
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good analgesia delivery which provide adequate pain control such intranasal and oral 
transmucosal (Lotsch et al., 2013). 
 
The intranasal route is a convenient form of delivery that is applicable to several 
opioids and has the potential for self-administration, combined with a rapid onset of action. It 
has been increasingly viewed as a new alternative route for drug administration and it has 
been proven to be useful in-hospital and out-of-hospital pain management (Prommer and 
Thompson, 2011) 
. 
It is important for a clinican in ED to know how to manage pain properly and decide 
which drug is better including the route of administration which may affect the onset and the 
ease of administration of the drug. Different route of drug administration will have different 
time of onset and less invasive route is much more preferred as it may avoid unnecessary 
difficulties. As in ED, it is best to treat pain in a fast and effective way. This might improve 





1.2.1 General Objective : 






1.2.2 Specific Objective :  
To compare mean of pain score between intranasal fentanyl with intravenous tramadol and 
intravenous tramadol alone. 
To compare mean arterial pressure and incidence of side effects in between both group. 
 
1.2.3 Research Question : 
1. Does intranasal fentanyl together with intravenous tramadol reduce pain score better than 
intravenous tramadol alone? 
2. Does intranasal fentanyl together with intravenous tramadol reduce mean arterial pressure 
more than intravenous tramadol alone? 
3. Does intranasal fentanyl together with intravenous tramadol cause more side effects than 
intravenous tramadol alone? 
 
1.2.4 Hypothesis : 
Intranasal fentanyl together with intravenous tramadol has significant difference of mean than 
intravenous tramadol alone as an analgesia. 
 
1.2.5 Term Definition : 
Pain : An unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage (Merskey et al., 1986) 
Intranasal : Occurring within or administration through nose. 
Intravenous : Within or administered through venous. 
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Visual Analog Scale : pain measurement instrument. 


















2. LITERATURE REVIEW 
 
 Pharmacologic agent administration for analgesia is still the main modality to treat 
pain. It is important to select appropriate pharmacologic agent for analgesia to effectively 
manage pain as in acute pain usually accompanied by anxiety. There are various type of 
analgesic available in emergency department and tramadol and fentanyl is part of it.  
 
 Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage (Merskey et al., 1986). It is an 
unpleasant sensation that brain interprets after a peripheral lesion of nociceptive intensity 
(MOTOC et al., 2010). There are 3 types of fibers that carry pain signals to the brain which 
are A-beta, A-delta and the unmyelinated C fibers (Ard and Haines, 2002).  
 
 Physiological pain model focus on underlying causative mechanism which can be due 
to either nociceptive pain which is a normal functioning nociceptive system alerting the brain 
to bodily injury such as pain due to acute musculoskeletal injury or neuropathic and central 
pain which is a manifestation of nociceptive system dysfunction (Woessner, 2002).  
 
 As for management of pain in general, WHO ladder for pain management can be used 
as a guide for choosing the proper analgesia which suggest the use of opioids in pain 
management (Vargas-Schaffer, 2010). Tramadol a synthetic opioid of the aminocyclohexanol 
group and is widely being used in management of moderate to severe pain in emergency 
department (Ahmad et al., 2010). It is usually administered via oral, intramuscular and 
intravenous route and it has analgesic potency equivalent to pethidine (Smith et al., 2011). As 
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for fentanyl, it is a synthetic phenylpiperidine derivative which is 50 to 80 times more potent 
analgesic than morphine (Smith et al., 2011). 
 
Opiod is the main analgesia used in moderate to severe pain but its use is usually 
affected by concern that it can cause adverse event such as hypotension and sometime we are 
concerned of drug seeking behavior (Ducharme, 2015) . At the same time opioids also may 
cause vomiting and nausea. Due to this reason we need to consider few factors to make 
proper use of opiod as analgesia. Example of this include route of administration and desired 
time of onset, initial dose, frequency of administration which is titrated against analgesic 
response, concurrent use of nonopioid analgesics and adjunctive agent, incidence and severity 
of side effects  and lastly whether the analgesic will be continued in an inpatient or 
ambulatory setting (Ducharme, 2015).  
 
Despite of all documented adverse event related with opioid use, there are differences 
between clinical pharmacology and laboratory pharmacology for opioids. There will be 
differences when opioids is given to a person who suffer from pain and a person who is not in 
pain. As an example, respiratory depression was seen in studies of volunteers who are not in 
pain but respiratory depression was kept to a minimum when appropriate regular doses of 
opioids are given to patients with pain (McQuay, 1999). 
 
According to McQuay (1999), to attain differences of time of onset of an opiod is 
achieved by changing the route of administration or formulation. Fast onset of effect is not a 
critical factor if the patient is receiving continuous analgesic for chronic pain. However, it is 




Opioids act at the relay station of nociceptive-propagating pathways. It has the 
property to bind at specific receptor site at pre- and post terminal nerve endings resulting in 
an inhibition of a release of the excitatory neurotransmitter of the nociceptive-propagating 
pathways. Due to the inhibition, impulse is interrupted and nociceptive signal is no longer 
transmitted. It is different if compared to analgesic which has peripheral site of action (Freye, 
2008). 
 
 Anesthetic delivery has been the same for the past 150 years. The new routes and 
delivery systems promise improved convenience, improved safety, increased effectiveness, 
increased bioavailability, continuous delivery with fewer peaks and valleys, decreased side 
effects, decreased dosage and frequency of administration, and decreased cost. One of the 
important delivery systems in the near future is transmucosal drug delivery which include 
nasal, buccal, ocular, rectal, and mucosa (Stanley, 2000). Mucosal membranes are thinner and 
more highly vascularized, there is the potential of giving large molecules, like peptides and 
proteins. Because their drug delivery is much faster, the transmucosal systems also allow the 
possibility of titrating drugs and thus provide enhanced flexibility (Stanley, 2000). 
 
The nasal mucosa is highly vascularized. The blood-vascular system is only separated 
of the nasal lumen by two cell layers (Marttin et al., 1998), which offers the possibility of a 
rapid drug absorption. Nasal drug delivery can be an attractive alternative to intravenous and 
intramuscular injections. This is one good reason to promote intranasal route for drug 
administration. Intravenous and intramuscular administration is invasive and sometime may 
cause discomfort to patient (Hartstein and Barry, 2008). At the same time it will take some 
time for clinician to establish an intravenous line for drug administration. The human nasal 
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mucosa contains drug-metabolising enzymes but the extent and clinical significance of 
human nasal first-pass metabolism is unknown (Dale et al., 2002).  
 
The widespread interest in intranasal route for therapeutic purposes other than the 
topically nasal drug delivery arises from the particular anatomical, physiological and 
histological characteristics of the nasal cavity, which provides potential for rapid systemic 
drug absorption and quick onset of action (Mygind and Dahl, 1998). In addition, intranasal 
absorption avoids the gastrointestinal and hepatic presystemic metabolism, enhancing drug 
bioavailability in comparison with that obtained after gastrointestinal absorption (Leonard et 
al., 2007). 
 
 A study of patient-controlled intranasal analgesia (PCINA) in acute 
postoperative pain  which used intravenous fentanyl solution for intranasal route showed that 
patient satisfaction is comparable to patient-controlled intravenous analgesia and intranasal 
route for analgesia represents an interesting alternative non-invasive method (Striebel et al., 
1996). Intranasal fentanyl at the standard intravenous concentration of 50 mcg/mL appeared 
to be an effective analgesic for children in the emergency setting presenting with acute 
injuries (Crellin et al., 2010). As compare to other intranasal analgesic agent, fentanyl in 
concentration of 50 mcg/mL is easily available without need to further concentrate the drug 
preparation which may be costly. 
 
 Previously intranasal diamorphine shown to be as efficacious as intramuscular 
morphine sulphate with a plus point that it was better tolerated and accepted especially in 
children. Intranasal diamorphine is effective, safe, and acceptable method of analgesia for 
children requiring opiates in the A & E department (Wilson et al., 1997). However because of 
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its limited availability cause limitation of its use. As for fentanyl, it is widely available in our 
emergency department which make it easily accessible in daily practice. 
 
 Intranasal fentanyl has been shown to have therapeutic serum levels in 2 minutes, 
reflecting the good venous outflow of nasal mucosa and the bypassing of the liver, avoiding 
hepatic first-pass metabolism (Borland et al., 2005). Intranasal fentanyl has a bioavailability 
of 89%, with a short onset of action approximately 7 min and duration times approximately 1 
hour (Panagiotou and Mystakidou, 2010). In the clinical setting, intranasal fentanyl can be 
administered promptly into the nasal cavity without the delays resulting in effective 
analgesia. As per previous study for intravenous tramadol, onset of the effect of intravenous 
tramadol already can be seen at 10 minutes post drug administration which resulted in a 
significant pain reduction (Ahmad et al., 2010). Hence this study used 10 minutes as the time 
to measure pain score to compare which group provide pain relief faster than the other group. 
 
According to Hansen and Dahl (2013), there were only limited quality evidence exists 
for the efficacy of intranasal fentanyl in ED. More double-blinded, randomized controlled 
trials are needed to validate the use of intranasal fentanyl in ED. It must be highlighted that 
only three studies involving use of intranasal fentanyl which involved adults related to 
presentation to emergency department and all of them were done in prehospital setting 
(Hansen and Dahl, 2013).  
 
Previous study done in emergency department which involved children showed that 
there were no significant adverse effects of intranasal fentanyl noted (Borland et al., 2007). In 
another study done in emergency department, there were no significant desaturations, 
reductions in respiratory rate or bradycardias observed (Younge et al., 1999). There was also 
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no significant differences in pulse rate, respiratory rate, blood pressure or oxygen saturations 
even when improvement in pain scores had been achieved (Borland et al., 2002). This is very 
important in choosing pharmacologic agent for analgesia as clinician would prefer analgesia 
with less adverse effects and ease of administration. 
 
 Prehospital use intranasal fentanyl in adult population was also promising as previous 
study done in prehospital setting showed that intranasal fentanyl was an effective analgesic 
agent and it may be offset to some degree than intravenous morphine as it requires no 
intravenous access to administer even if IV morphine appear more effective than intranasal 
fentanyl (Middleton et al., 2010).  
 
As per survey done by Paediatric Research in Emergency Departments International 
Collaborative (PREDICT) done in Australia and New Zealand which include all pediatric 
emergency department and several large mixed emergency department, it is recommended 
that intranasal fentanyl dose to be use is 1.5 mcg/mL and certain emergency department 
reported use of intranasal fentanyl dose from 1-2 mcg/mL. Eleven emergency department use 
standard intravenous formulation 50mcg/mL solution and two other emergency department 
use a specially produced concentrated fentanyl solution at 150 mcg/mL (Herd and Borland, 
2009). This showed that the easily available fentanyl citrate is effective and can be used as 
analgesia in emergency department. However there were limited evidence regarding its use in 
adults. 
 
Visual analog scale (VAS) are among the most commonly used measures of pain 
intensity in clinical trials (Jensen et al., 2003). It is a unidimensional scale which is easy to 
use, requires no verbal or reading scale and is sufficiently versatile to be employed in a 
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variety of setting (Gallagher et al., 2001). Based on previous study, findings suggested that 
VAS ratings of 0 to 4 milimeter (mm) can be considered as no pain; 5 to 44 mm as mild pain; 
45 to 74 mm as moderate pain; 75 to 100 mm as severe pain (Jensen et al., 2003). VAS is a 
self-completed by the respondent. The respondent is asked to place a line perpendicular to 
VAS line at the point that represents their pain intensity. Using a ruler, the score is 
determined by measuring the distance (mm) on the 10-cm line between the “no pain” anchor 
and the patient's mark, providing a range of scores from 0–100  (Hawker et al., 2011). It takes 
less than one minute to complete (Downie et al., 1978). 
 
There were limited evidence regarding the use of intranasal fentanyl in adults with 
acute pain during their presentation at emergency department  and for this reason, it is 
important for this study to be done. Tramadol is a common drug used in emergency 
department. Previous study already proves that fentanyl administered intranasally has good 
analgesia effect with no significant adverse effect (Hansen and Dahl, 2013). It is fast to 
administer compare with intravenous route which require placement of intravenous catheter 
for drug administration. It is important to know whether intranasal fentanyl combined with 
intravenous tramadol is superior in efficacy compared to intravenous tramadol which is a 
common analgesic drug used in acute trauma pain which require time for intravenous 
administration. Prolonging patient in painful state will cause more anxiety which may lead to 









3.1 Study Design 
A prospective, randomized, open-label single centre study was conducted for a period 
of 6 months from November 2014 to April 2015 to evaluate the efficacy of the use of 
intranasal fentanyl as an adjunct analgesia on top of intravenous tramadol in acute 
musculoskeletal injuries with moderate to severe pain. This study was approved by Human 
Ethics Committee of Universiti Sains Malaysia. 
 
3.2 Study setting and population 
 
 This study was conducted in Emergeny Department of Hospital Universiti Sains 
Malaysia (HUSM) which is a 750-bedded tertiary referral centre and teaching hospital 
located in the east coast of Peninsular Malaysia.  
 
3.3 Study protocol 
 
 All adult patients (above 18 years old including elderly) who presented to the 
emergency department of HUSM within the stipulated study period with musculoskeletal 
injuries which include soft tissue injury and bone fractures in moderate to severe pain were 




 Patients with polytrauma or significant co-morbidities such as hypertension, diabetes 
mellitus and cardiovascular diseases, pregnant patients as well as those with hemodynamic 
instability requiring resuscitation and stabilization were excluded. As this study involves 
intranasal route of administration, any patient with rhinopharyngitis or any intranasal 
pathologies were also excluded. Similarly, patients without the mental capacity to evaluate 
pain severity as well as those with visual impairment and unable to mark on the line of the 
Visual Analog Scale (VAS) were also excluded. Inevitably, any patients who had received 
any form of opioid as well as those with allergic history to opioid were also excluded. 
 
Written consent was obtained if the patients fulfilled the study criteria.. Pain score 
using visual analogue scale (VAS) a unidimensional pain scale that is easy to use, requires no 
verbal or reading scale which consist of 100 mm horizontal line was first obtained by asking 
the patient to place a mark ‘X’ to represent their pain intensity on the sheet of paper printed 
with VAS.  A score of 45 mm to 74 mm was classified as moderate pain and score of 75 mm 
to 100 mm was classified as severe pain. The patients were then told that they would be 
allocated to either treatment package A or treatment package B. The allocation was concealed 
in an envelope and the patient was instructed to draw one of the envelopes in the box. The 
serial number of the paper in the envelope obtained was then matched with the table of block 
randomization that had been pre-generated using a random sequence generator online 
program. Patients allocated to one type of treatment did not know the type of treatment in the 
other arm. So, although it was an open-label study, as the patients eventually knew the type 
of treatment received, the patients were blinded to treatment in the other arm. 
 
 For patients who received intranasal fentanyl on top of intravenous tramadol, 
intranasal fentanyl was first administered at a dose of 1.5 mcg/kg with solution concentration 
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of 50mcg/ml using LMA MAD NasalTM. To do so, the patient was propped up to an 
inclination of 45 degrees before the fentanyl was delivered in increments of 0.25 mls per slow 
push into patients right and left nostrils alternately for the next five minutes. The intravenous 
access was established concurrently within 2 minutes of the intranasal fentanyl administration 
and intravenous metoclopramide 10 mg was then administered as an anti-emetic for all 
patients. This was followed by intravenous tramadol 2mg/kg administration as slow bolus 
over 1 minute. All treatment in both group were given within 5 minutes and at this 5 minutes, 
it was marked as time_0.  
 
As for the control group, intravenous access was established and only intravenous 
metoclopramide 10 mg was administered as an anti-emetic and was followed by intravenous 
tramadol 2mg/kg as a slow bolus over 1 minute. After 10 minutes from time_0, the same 
VAS were used again to assess patients pain intensity in both group. No other procedures was 































Figure 3.1 : Flow chart of the study 
 
 
Patient with acute trauma pain in moderate to severe pain in Emergency Department 
Patient fulfil inclusion and exclusion criteria 
Patient consented to participate in this study 
Patient agree 
Patient not agree 
Data collection : History taking, physical examination including 
vital sign, pain score assessment using VAS, medication 
administration, repeat VAS and vital sign 
Not included in study 







Manuscript writing and publication 
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3.4 Measurement or key outcome 
 
The primary outcome was the visual analogue scale reduction from pre-medication with 
either intranasal fentanyl with intravenous tramadol or intravenous tramadol alone and post-
medication at 10 minutes. Secondary outcome was the mean arterial pressure and heart rate 




3.5 Sample size calculation 
 
3.5.1 Sample size calculation   
 
 Sample size was calculated using independent t-test (Dupont and Plummer, 1990). 
Calculation done with PS Power and Sample Size Calculations Version 3.0 software. 
 
 Calculated sample size will be as below : 
 










SD derived from previous study of intravenous tramadol at 10 minutes (Ahmad et al., 2010) 
In a previous study the response at 10 minutes within each subject group was 
normally distributed with standard deviation 15.  If the true difference in the experimental 
and control means is 20, we will need to study 10 experimental subjects and 10 control 
α = 0.05 SD = 15 
δ = 20 m (ratio) = 1 
power = 
0.8 N (size) = 10 per group 
  
N with 10% drop out per group 
= 11 
  Total sample size = 22 
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subjects to be able to reject the null hypothesis that the population means of the experimental 
and control groups are equal with probability (power) 0.8.   The Type I error probability 
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Injuries 
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Introduction: Intra-nasal fentanyl, as an alternative route of analgesic administration, has 
been shown to be effective particularly in pediatric population and in prehospital setting.  
Studies on such use among adult patients in emergency department are limited. Methods: An 
open-label study was conducted to evaluate the effectiveness of adding 1.5 mcg/kg intranasal 
fentanyl on top of 2 mg/kg intravenous tramadol (FENTANYL_TRAMADOL, n = 10) as 
compared to 2 mg/kg intravenous tramadol alone (TRAMADOL, n = 10) in adult patients 
with acute musculoskeletal injuries in moderate to severe pain.  Results:  When analyzed 
using independent t-test, the mean visual analog scale (VAS) difference between pre- and 10-
minute post-intervention was found to be 29.8 mm (SD +/- 8.4 mm) in the 
FENTANYL_TRAMADOL arm and 19.6 mm (SD +/- 9.7 mm) in the TRAMADOL arm 
[t(8) = 2.515, p = 0.022, 95% confidence interval (CI) 1.68 to 18.72 mm].  A significantly 
greater albeit transient reduction in mean arterial pressure 10 minutes post intubation was 
noted in the FENTANYL_TRAMADOL arm as compared to those in the TRAMADOL arm 
(13.35 mmHg vs 7.65 mmHg, using Mann-Whitney U test with U-value = 21.5; p = 0.029; r 
= 0.48). Patients in the FENTANYL_TRAMADOL arm also experienced a higher incidence 
of transient dizziness 10 minutes post-intervention. Conclusion: Although effective, intra-
nasal fentanyl in adult patients may not be ready for primetime as it may result in significant 
reduction in blood pressure. 
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An Open Label Randomized Controlled Trial On The Efficacy Of 
Adding Intranasal Fentanyl To Intravenous Tramadol In Patients 





Although pain is a common presentation in emergency departments (Tanabe and 
Buschmann, 1999b), lack of pain control or ‘oligoanalgesia’ frequently occurs (Motov and 
Khan, 2009). In a crowded emergency department, time to analgesia is often prolonged 
(Hwang et al., 2006) and this can be detrimental as the quality of pain management affects 
patients’ outcomes. 
 
 One of the factors that improves the timing of pain management is the route of 
analgesia administration. Intra-nasal route of analgesia administration has recently been 
advocated as an alternative method to overcome the problem of delayed drug administration 
(Prommer and Thompson, 2011). In properly selected patients, intranasal route reduces time 
from drug administration to onset of action, reduces the burden of staff resources, eliminates 
needle stick exposure risk and eliminates injection pain (Wolfe and Braude, 2010). On the 
other hand, intravenous and intramuscular routes are relatively invasive and may cause 
discomfort to patients (Prommer and Thompson, 2011). Occasionally, clinicians may have 





Intranasal route enables rapid absorption because the nasal mucosa is a highly 
vascularised mucosa with its blood-vascular system separated from the nasal lumen by only 
two cell layers (Marttin et al., 1998). Furthermore, the intranasal route affords a large surface 
area (150 – 180 m2) (Shelley and Paech, 2008) for drug delivery and it eliminates the first 
pass metabolism (Leonard et al., 2007); thus allows the drug to enter the cerebrospinal fluid 
via the olfactorial mucosa with immediate therapeutic effect (Hansen and Dahl, 2013). For 
example, intranasal fentanyl has been shown to achieve therapeutic serum levels within 2 
minutes of administration reflecting the good venous outflow of nasal (Borland et al., 2005). 
Additionally, there were no significant oxygen desaturations, reductions in respiratory rate 
nor heart rates in patients given intranasal fentanyl (Younge et al., 1999). 
 
 Tramadol is a synthetic opioid of the aminocyclohexanol group and it has been shown 
to possess analgesic potency equivalent to that of pethidine (Lee et al., 1993). Fentanyl is a 
synthetic phenylpiperidine derivative with analgesic potency 50 to 80 times that of morphine 
(Smith et al., 2011). Besides, fentanyl has a rapid onset of action within 6 to 8 minutes 
following intranasal administration due to its high lipid solubility (Clavijo et al., 2012). In 
studies done in prehospital setting, it has been shown that intranasal fentanyl is as effective as 
intravenous morphine as analgesia in both adult patients (Rickard et al., 2007) as well as 
paediatric patients (Bendall et al., 2011). 
 
 Although the evidence regarding intranasal fentanyl use in emergency department is 
limited, the results were promising with some studies showing that intranasal fentanyl is as 
effective as intramuscular morphine (Younge et al., 1999). In another study done in 
emergency department setting, intranasal fentanyl has been shown to be comparable to 
intravenous morphine in reducing pain following acute long bone fractures among pediatric 
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population (Borland et al., 2007). Similarly, another study showed that intranasal fentanyl 
provides effective analgesia for pediatric patient with painful orthopaedic trauma (Saunders 
et al., 2010).  
 
Nonetheless, although intranasal fentanyl has been shown to be effective, most of the 
studies on intranasal fentanyl use in emergency department were done on paediatric 
population (Hansen and Dahl, 2013). There were limited studies of intranasal fentanyl use in 
adult patients in emergency department with musculoskeletal injury. Most of the study  which 
related to emergency department were the one which involved prehospital care. 
 
MATERIALS AND METHODS 
 
 Therefore, a prospective, randomized, open-label study was conducted to evaluate the 
effectiveness of adding intranasal fentanyl on top of intravenous tramadol in acute 
musculoskeletal injuries with moderate to severe pain. This study was approved by the 
Human Ethics Research Committee of Universiti Sains Malaysia.  
 
The primary outcome of this study was the subjective improvement of pain severity as 
measured using the degree of visual analog scale (VAS) reduction at 10 minutes post-
medication across both arms. Secondary outcomes were the changes of mean arterial 
pressures and heart rates before and 10-minute after interventions as well as the incidences of 








 This study was conducted in the emergency department of Hospital Universiti Sains 
Malaysia (HUSM), a 750-bed tertiary referral centre and teaching hospital located in the east 
coast of Peninsular Malaysia.  All adult patients (above 18 years old) who presented within 
the stipulated study period with musculoskeletal injuries in moderate to severe pain were 
recruited consecutively after obtaining written consent. 
 
 Patients with polytrauma or significant co-morbidities such as hypertension, diabetes 
mellitus and cardiovascular diseases, pregnant patients as well as those with hemodynamic 
instability requiring resuscitation and stabilization were excluded. As this study involves the 
intranasal route of administration, any patient with rhinopharyngitis or any intranasal 
pathology were excluded. Similarly, patients without the mental capacity to evaluate pain 
severity as well as those with visual impairment and unable to mark on the line of the Visual 
Analog Scale (VAS) were also excluded. Inevitably, any patients who had received any form 
of opioid as well as those with allergic history to opioid were excluded. 
 
The sample size was estimated based on the two-means formula using independent t-
test with α = 0.05 and power = 0.8. Based on a previous study done on the same population 
using intravenous tramadol (Ahmad et al., 2010), the standard deviation of VAS change was 
taken as 15 mm and the estimated VAS difference was targeted at 20 mm. Accounting for a 








Pain severity was assessed using the Visual Analog Scale (VAS). Moderate pain is 
defined as 45 mm to 74 mm and severe pain is defined as 75 mm to 100 mm on VAS (Jensen 
et al., 2003). The intranasal delivery of fentanyl was performed using a mucosal atomisation 
device (LMA MAD NasalTM). Due to ethical consideration and the unconventionality of 
intranasal route, a comparative intranasal placebo administration in the tramadol arm was not 




 Pain score using VAS was first obtained by asking the patient to place a mark ‘X’ to 
represent their pain intensity. Written consent was then obtained if the patients fulfilled the 
study criteria. The allocation was concealed and the patient was instructed to draw the 
allocation paper from an opaque envelope. Patients allocated to one type of treatment did not 
know the type of treatment in the other arm.  
 
 For patients who received intranasal fentanyl on top of intravenous tramadol 
(FENTANYL_TRAMADOL), intranasal fentanyl was first administered at a dose of 1.5 
mcg/kg with the solution concentration of 50 mcg/ml using the LMA MAD NasalTM. To do 
so, the patient was propped up to an inclination of 45 degrees before the fentanyl was 
delivered in increments of 0.25 ml via slow push into the patient’s right and left nostrils 
alternately for the next five minutes until the calculated dose had been achieved. The 
intravenous access was then concurrently established within 2 minutes after the intranasal 
fentanyl administration. Intravenous metoclopramide 10 mg was administered as an anti-
